KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Short-term Investments (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Short-term Investments data on record, last reported at $642.0 million in Q4 2025.

  • For Q4 2025, Short-term Investments rose 47.11% year-over-year to $642.0 million; the TTM value through Dec 2025 reached $642.0 million, up 47.11%, while the annual FY2025 figure was $642.0 million, 47.11% up from the prior year.
  • Short-term Investments reached $642.0 million in Q4 2025 per ACAD's latest filing, up from $589.0 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $642.0 million in Q4 2025 and bottomed at $112.0 million in Q1 2023.
  • Average Short-term Investments over 5 years is $351.0 million, with a median of $299.2 million recorded in 2022.
  • Peak YoY movement for Short-term Investments: tumbled 53.55% in 2023, then soared 137.35% in 2024.
  • A 5-year view of Short-term Investments shows it stood at $373.3 million in 2021, then fell by 19.1% to $302.0 million in 2022, then decreased by 17.14% to $250.2 million in 2023, then skyrocketed by 74.42% to $436.4 million in 2024, then soared by 47.11% to $642.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $642.0 million in Q4 2025, $589.0 million in Q3 2025, and $508.4 million in Q2 2025.